A comparison of Sars-Cov-2 vaccine platforms: the CoviCompare project

Neutralizing antibodies against SARS-CoV-2 variants following mRNA booster vaccination in adults older than 65 years

“…These patients received a single dose of BNT162b2 vaccine according to the French COVID-19 immunization guidelines at the time. Participants were healthy adults or with stable medical condition (defined as disease not requiring change in therapy or hospitalization for worsening disease during 3 months before enrolment nor expected significant change in foreseeable future) 10 .…”

“…The CoviCompare research program launched in France in January 2021 aims to assess the immunogenicity of different COVID 19 vaccine platforms in older people (65 years and older) compared to younger people (18–45 years) 10 . In CoviCompareM and CoviCompareP trials (ClinicalTrials.gov: NCT04748471 and NCT04824638), participants with negative SARS-CoV-2 serology at inclusion and no previous history of COVID-19 received two doses of either mRNA-1273 or BNT162b2, 28 days apart, as primary vaccination.…”

SARS-CoV-2 Nanovaccine Composed of Microfluidic-Produced Gold Nanoparticles Induces Neutralizing Immune Responses

“…The outbreak of the coronavirus disease (COVID-19) in December 2019 has raised the need to establish new effective and versatile vaccine platforms, whose adaptation to potential future threats is reasonably fast and technically plausible . Among the vaccinal strategies that responded to the COVID-19 urgency were the new mRNA and recombinant adenovirus vectorized vaccines, as well as the more traditional vaccines consisting of inactivated virus particles and subunit vaccines based on recombinant viral proteins. , In this context, the receptor binding domain (RBD) protein has been selected as the core antigen of most vaccine formulations. The RBD is a region of the SARS-CoV-2 spike protein that mediates the binding to host cell angiotensin-converting enzyme receptors that are widely expressed in epithelial cells of the lungs, heart, kidney, and intestine …”

Progress, pitfalls, and path forward of drug repurposing for COVID-19 treatment

“…This is the case for all the main vaccine platforms that have proven most successful so far, such as vaccines based on mRNA (BNT162b2 and Spikevax) or adenoviral vector vaccines (ChAdOx1-S and Ad26.COV2.S). 7 Therefore, the evolution of the S-glycoprotein remains closely monitored to track the development of mutations that may favor immune evasion ( Figure 1 ). In this regard, some of the so-called variants of concern (VOCs), that is, B.1.1.7 (alpha), B.1351 (beta), P.1 (gamma), B.1.617.2 (delta), and B1.1.529 (omicron) 8 are already characterized by increased transmissibility and severity, or as compared with the original strain.…”